Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2–3 study

Autor: Ren, Zhenggang, Xu, Jianming, Bai, Yuxian, Xu, Aibing, Cang, Shundong, Du, Chengyou, Li, Qiu, Lu, Yinying, Chen, Yajin, Guo, Yabing, Chen, Zhendong, Liu, Baorui, Jia, Weidong, Wu, Jian, Wang, Junye, Shao, Guoliang, Zhang, Bixiang, Shan, Yunfeng, Meng, Zhiqiang, Wu, Jianbing, Gu, Shanzhi, Yang, Wei, Liu, Chao, Shi, Xuetao, Gao, Zhenyuan, Yin, Tao, Cui, Jiuwei, Huang, Ming, Xing, Baocai, Mao, Yilei, Teng, Gaojun, Qin, Yanru, Wang, Jinhai, Xia, Feng, Yin, Guowen, Yang, Yong, Chen, Mingxia, Wang, Yan, Zhou, Hui, Fan, Jia *
Zdroj: In The Lancet Oncology July 2021 22(7):977-990
Databáze: ScienceDirect